Injectable Lipid-Lowering Therapies Across the Chronic Kidney Disease Spectrum: Evidence, Safety, and a Stage-Specific Clinical Framework

Abstract

Chronic kidney disease (CKD) confers a high burden of atherosclerotic cardiovascular disease (ASCVD) and a characteristic, evolving dyslipidaemia that is incompletely addressed by conventional care. Statin-based therapy remains first-line in most non-dialysis CKD populations, yet many patients fail to reach lipid goals or remain at substantial residual risk. This structured narrative review evaluates injectable lipid-lowering agents across the CKD spectrum, focusing on the pharmacology and clinical utility of therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). The monoclonal antibodies evolocumab and alirocumab are subcutaneous biologics that bind circulating PCSK9, prevent PCSK9-mediated degradation of the low-density lipoprotein (LDL) receptor, and enhance hepatic LDL-cholesterol (LDL-C) clearance. Their catabolic elimination and negligible cytochrome-P450 interaction burden are advantageous in polypharmacy-heavy CKD care. Inclisiran is a hepatocyte-directed, GalNAc-conjugated small interfering RNA that silences PCSK9 messenger RNA, enabling durable LDL-C lowering with twice-yearly maintenance dosing after initiation. Across major programmes, injectable PCSK9 inhibition produces a ~50–60% LDL-C reduction, with consistent efficacy and safety across renal function strata, although outcome data in advanced CKD and dialysis remain limited. Importantly, cardiovascular outcome benefit is established for the monoclonal antibodies evolocumab and alirocumab, whereas inclisiran currently has robust LDL-C-lowering evidence but no completed cardiovascular outcome trial; these agents should not be regarded as having equivalent outcome evidence. Historical dialysis statin trials showed attenuated or neutral cardiovascular benefit, underscoring the biological and trial-design complexity of late-stage kidney disease and the need for dedicated injectable-era trials. We propose a stage-specific framework for integrating injectable therapies into CKD pathways—covering patient selection, sequencing, monitoring and implementation—and outline priorities for CKD-enriched outcome trials, kidney-relevant endpoints, and the integration of emerging lipoprotein(a)-targeted injectables into cardio-renal risk reduction.